
    
      1. Subcutaneous Administration of NRG-1 is well tolerated by CHF patients

        2. Subcutaneous Administration of NRG-1 improves the cardiac function of CHF patients

        3. Assessment of relative bioavailability of NRG-1 by Subcutaneous Administration
    
  